NerdWallet's future growth may disappoint despite past performance and robust revenue growth, due to their high P/S ratio and significant risks. The current share prices could be unsustainable long-term due to potential lower revenue growth.
Despite the recent gains, NerdWallet's high price-to-sales ratio may not be justified given the slower-than-industry growth forecast. There's a risk of future disappointment for investors if the P/S falls to levels more in line with the growth outlook.
NerdWallet's CEO sees the new card as a triple win - a useful tool for consumers to establish credit affordably, larger customer base for banks and a wider, engaged audience for NerdWallet, though the company won't directly monetize the card.
Gainers: •$Ballys(BALY.US)$+6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22) •$Ferguson(FERG.US)$+3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program) •$Bausch Health(BHC.US)$+3.3% (chairman resigns) •$賽諾菲安萬特(SNY.US)$+3.2% (Sanofi-GSK first to report a successful efficacy study against ...
NerdWallet股票討論區
⚠️ Stocks are Crashing…
Top Stocks to Buy Now!!
$NerdWallet(NRDS.US)$$美國電塔(AMT.US)$$National Storage Affiliates Trust(NSA.US)$$Extra Space Storage(EXR.US)$$戴文能源(DVN.US)$$新紀元能源(NEE.US)$$NextEra Energy Partners LP(NEP.US)$$佩恩國民博彩(PENN.US)$
11/3 Watchlist
$Chewy(CHWY.US)$$Coinbase(COIN.US)$$Datadog(DDOG.US)$$DraftKings(DKNG.US)$$Forza X1(FRZA.US)$$NerdWallet(NRDS.US)$$PayPal(PYPL.US)$$高通(QCOM.US)$$Roku Inc(ROKU.US)$$Twilio(TWLO.US)$
專欄Today's pre-market stock movers: FDX, REV, BCS, KMX and more
• $Ballys(BALY.US)$ +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)
• $Ferguson(FERG.US)$ +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)
• $Bausch Health(BHC.US)$ +3.3% (chairman resigns)
• $賽諾菲安萬特(SNY.US)$ +3.2% (Sanofi-GSK first to report a successful efficacy study against ...
暫無評論